Profile picture

Doctor Mikhail Kosiborod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)
Follow
Logo ESC

Contributor content

The obesity phenotype of HFpEF: new therapies on our door step?
Session
The obesity phenotype of HFpEF: new therapies on our door step?
27 August 2023
Read more
Finerenone: a disease-modifying therapy for heart and kidney protection
Session
Finerenone: a disease-modifying therapy for heart and kidney protection
27 August 2023
Read more
Tackling the risk of hyperkalaemia through guideline-recommended heart failure therapy
Session
Tackling the risk of hyperkalaemia through guideline-recommended heart failure therapy
26 August 2023
Read more
HFpEF: a great unmet need?
Session
HFpEF: a great unmet need?
22 May 2023
Read more
Breaking barriers in guideline-based RAASi-therapy: solving issues with hyperkalemia
Session
Breaking barriers in guideline-based RAASi-therapy: solving issues with hyperkalemia
20 May 2023
Read more
What's the next STEP in HFpEF?
Session
What's the next STEP in HFpEF?
22 May 2022
Read more
Glucagon-like peptide 1 receptor agonists in clinical cardiology practice
Session
Glucagon-like peptide 1 receptor agonists in clinical cardiology practice
28 August 2021
Read more
Consequences of COVID-19 in heart failure: one year on
Session
Consequences of COVID-19 in heart failure: one year on
27 August 2021
Read more
6 years on, what have we learned from Real World use of PCSK9i?
Session
6 years on, what have we learned from Real World use of PCSK9i?
27 August 2021
Read more
Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk
Session
Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk
3 September 2019
Read more

ESC 365 is supported by

novartis Explore sponsored resources